Clinical utility and psychometric properties of the Apathy Evaluation Scale.


Journal

Rehabilitation psychology
ISSN: 1939-1544
Titre abrégé: Rehabil Psychol
Pays: United States
ID NLM: 0365337

Informations de publication

Date de publication:
Aug 2020
Historique:
entrez: 18 8 2020
pubmed: 18 8 2020
medline: 16 6 2021
Statut: ppublish

Résumé

The Apathy Evaluation Scale (AES) is a tool utilized with individuals with brain injury, neurocognitive disorders, and other mixed populations to quantify and characterize apathy in adults. The scale "treats apathy as a psychological dimension defined by simultaneous deficits in the overt behavioral, cognitive, and emotional concomitants of goal-directed behavior." It has three versions: self-rated (AES-S), clinician-rated (AES-C), and informant-rated (AES-I). Using factor analysis, Marin and colleagues identified three factors for the scale, including general apathy, disinterest or amotivation, and lack of concern. The psychometric properties of the AES have been examined in various clinical cohorts, including individuals with Alzheimer's disease (AD), traumatic brain injury (TBI), acquired brain injury, multiple sclerosis, severe mental illness, and cognitively healthy middle-aged cohort who are at risk for AD. The AES is a useful, reliable, and valid instrument to quantify and measure severity of apathy symptoms in adults. It is important to note that the AES-C and AES-S were able to discriminate apathy from depression and anxiety better than the AES-I did. It has been translated into Japanese, Portuguese, German, and Turkish. As a neuropsychiatric symptom, apathy should be measured in examining problems of relevance to psychology, psychiatry, and neurology, which may aid in understanding motivation, prognosis, and differential diagnosis. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

Identifiants

pubmed: 32804534
pii: 2020-59952-004
doi: 10.1037/rep0000356
pmc: PMC8127218
mid: NIHMS1698571
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

311-312

Subventions

Organisme : NIA NIH HHS
ID : R01 AG054059
Pays : United States

Références

Eur Psychiatry. 2008 Jan;23(1):33-9
pubmed: 18029152
Brain Inj. 2002 Jun;16(6):509-16
pubmed: 12119086
Fortschr Neurol Psychiatr. 2006 Dec;74(12):714-22
pubmed: 17167730
Psychol Med. 1999 Mar;29(2):447-56
pubmed: 10218936
Brain Inj. 2009 Dec;23(13-14):999-1007
pubmed: 19891539
Brain Inj. 1998 Jan;12(1):87-92
pubmed: 9483342
Psychiatry Res. 1991 Aug;38(2):143-62
pubmed: 1754629
Neuropsychiatry Neuropsychol Behav Neurol. 2002 Sep;15(3):184-91
pubmed: 12218711
J Neurol Sci. 2014 Dec 15;347(1-2):295-300
pubmed: 25455303
Nihon Ronen Igakkai Zasshi. 2014;51(5):445-52
pubmed: 25492674
Am J Alzheimers Dis Other Demen. 2019 Feb;34(1):16-22
pubmed: 30103612

Auteurs

Beatrice Lee (B)

University of Wisconsin-Madison.

Carey Gleason (C)

William S. Middleton Memorial Veterans Hospital.

Emre Umucu (E)

University of Texas at El Paso.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH